HRH3 and Alzheimer disease: Compound 2, a fragment-like molecule with moderate H3R antagonist affinity and a significant increase in acetylcholine release, has exhibited excellent in vivo behavior that is similar to galantamine, suggesting that the proposed dual hypothesis may represent a new target for the treatment of AD.